TP53 and cancer: In cancer cell lines, as well as in vivo models and human samples, TRIB2 overexpression has been found to mediate resistance against different chemotherapeutic agents and targeted drugs, including 5-fluorouracil, via disruption of the AKT/FOXO and AKT/MDM2/p53 pathways [12].